ArticleInfection and immunity2000
Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Article in Infection and immunity, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 44 citations in OpenAlex.
- Trial
- Molecular characterization and immunoprotective potential of microneme protein 3 from Eimeria necatrix.Parasites & vectors · 2026Article
- Genetic diversity of merozoite surface protein-5 (MSP-5) of Plasmodium vivax isolates from Malaria patients in Iran.BMC infectious diseases · 2023Article
- Article
- Immunogenicity analysis of conserved fragments in Plasmodium ovale species merozoite surface protein 4.Malaria journal · 2020Article
- A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria.Frontiers in immunology · 2019Article
- Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.Malaria journal · 2015Article
- Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.Infection and immunity · 2014Article
- Overview of plant-made vaccine antigens against malaria.Journal of biomedicine & biotechnology · 2012Review
- Article
- Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.Infection and immunity · 2004Article
- Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.Infection and immunity · 2004Article
- Oral immunization with a recombinant malaria protein induces conformational antibodies and protects mice against lethal malaria.Infection and immunity · 2003Article
- Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.Infection and immunity · 2002Article
- Immunogenetics and the design of Plasmodium falciparum vaccines for use in malaria-endemic populations.The Journal of clinical investigation · 2002Review
- The Babesia bovis merozoite surface antigen 2 locus contains four tandemly arranged and expressed genes encoding immunologically distinct proteins.Infection and immunity · 2002Article
- Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam.Infection and immunity · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Plasmodium yoelii merozoite surface protein 4/5 (PyMSP4/5), expressed as a recombinant protein, was highly effective at protecting mice against lethal challenge with P. yoelii. There was a significant correlation between prechallenge antibody levels and peak parasitemia, suggesting that the homologues of PyMSP4/5 in Plasmodium falciparum are promising components of a subunit vaccine against malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.